Yazen Health, a leading healthcare platform dedicated to addressing obesity through innovative medication and lifestyle changes, has announced the successful closure of an oversubscribed €19.5 million Series A funding round. This significant investment will enable the company to enhance its growth trajectory and facilitate international expansion in its fight against the global obesity crisis.

Funding Details and Investors

The funding round was co-led by Evli Growth Partners from Finland and Helsana HealthInvest from Switzerland, with participation from Almaz Capital and Yabeo, both based in Germany. Existing Swedish investors Luminar Ventures and Aggregate Media also contributed to this financing effort. This support underscores the confidence investors have in Yazen's unique approach to obesity treatment, which combines cutting-edge weight loss medications with comprehensive lifestyle support.

Addressing a Global Health Crisis

Obesity is a pressing health issue affecting millions worldwide, and Yazen aims to provide a holistic solution that makes a meaningful impact. By integrating modern weight loss medications with a multidisciplinary team comprising doctors, dietitians, psychologists, and physiotherapists, Yazen has successfully assisted over 20,000 patients in Sweden. The company boasts an impressive retention rate of 70% after one year, demonstrating the efficacy of its comprehensive care model.

Yazen is already profitable in the Swedish market, and the new funds will be allocated toward scaling the business internationally. The company plans to solidify its presence in Spain, Norway, and the Netherlands, where it has already established a foothold, while also enhancing its pilot projects in the UK and Germany. With ambitions to triple its growth over the next two to three years, Yazen is focused on enhancing its service offerings, strengthening its organizational structure, and expanding into new countries, all in pursuit of a healthier global population.

Enhancing Patient Support Through Technology

A significant portion of the funding will also be directed toward the development of Yazen's mobile application and its holistic care services. The app is designed to provide patients with continuous support as they navigate their weight loss journeys. Yazen's integrated care model ensures that patients receive comprehensive assistance from a dedicated team of healthcare professionals, which is reflected in the company's excellent customer reviews and high levels of engagement. This collaborative approach, rather than solely relying on medication, is key to achieving successful outcomes for patients.

Leadership Changes and Future Directions

In conjunction with the funding round, Yazen has appointed Mikael Hed as the new Chairman of the Board. Hed, a founding partner at Evli Growth Partners and former CEO of Rovio Entertainment—best known for the Angry Birds franchise—brings invaluable experience in scaling international brands to Yazen. His leadership will be instrumental as the company embarks on its next phase of growth.

Fredrik Meurling, CEO and Founder of Yazen, expressed his pride in the company’s achievements thus far. He emphasized that the funding will empower Yazen to continue its mission of combating obesity on a global scale. Meurling noted, "With Mikael Hed as our new Chairman and the support of our new investors, we are better positioned than ever to make a difference."

Mikael Hed also shared his enthusiasm for Yazen’s innovative approach to obesity treatment, stating, "Yazen’s comprehensive offering has quickly demonstrated an impressive track record. I look forward to leading the board’s work and, together with both existing and new investors, continuing Yazen’s international expansion."

Yazen Health's successful funding round marks a significant milestone in its journey to transform obesity treatment. With a proven business model, strong leadership, and a commitment to holistic patient care, Yazen is poised for substantial growth and expansion. As the company looks to penetrate new markets and enhance its offerings, it remains focused on its mission to create healthier lives for individuals struggling with obesity. The combination of modern medication and a supportive care team positions Yazen as a formidable player in the global healthcare landscape.

As Yazen continues to innovate and expand, it sets a promising precedent in addressing one of the most critical health challenges of our time, making a lasting impact on the lives of thousands around the world.